PreComb is a privately held Swiss biotech company developing proprietary technologies to enable evidence-based treatment decisions in cancer. The founding and management team combines their longstanding expertise in 3D cell culture technologies, life science process automation, computational and operational excellence.
PreComb at a glance
PreComb’s proprietary 3DTwin® technology combines fully automated and clinically relevant drug testing with patient-derived biological tumor twins, AI-guided data analysis and response prediction. It is tailored to be implemented directly in the clinic for oncology research and precision medicine.
Together, we aim to advance personalized oncology for the best possible patient benefit.